JP2014207903A5 - - Google Patents

Download PDF

Info

Publication number
JP2014207903A5
JP2014207903A5 JP2014083444A JP2014083444A JP2014207903A5 JP 2014207903 A5 JP2014207903 A5 JP 2014207903A5 JP 2014083444 A JP2014083444 A JP 2014083444A JP 2014083444 A JP2014083444 A JP 2014083444A JP 2014207903 A5 JP2014207903 A5 JP 2014207903A5
Authority
JP
Japan
Prior art keywords
cancer
vector
pharmaceutical composition
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014083444A
Other languages
English (en)
Japanese (ja)
Other versions
JP5767733B2 (ja
JP2014207903A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014207903A publication Critical patent/JP2014207903A/ja
Publication of JP2014207903A5 publication Critical patent/JP2014207903A5/ja
Application granted granted Critical
Publication of JP5767733B2 publication Critical patent/JP5767733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014083444A 2007-02-28 2014-04-15 ブラキュリポリペプチドおよび使用方法 Active JP5767733B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90423607P 2007-02-28 2007-02-28
US60/904,236 2007-02-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009551830A Division JP5596980B2 (ja) 2007-02-28 2008-02-27 ブラキュリポリペプチドおよび使用方法

Publications (3)

Publication Number Publication Date
JP2014207903A JP2014207903A (ja) 2014-11-06
JP2014207903A5 true JP2014207903A5 (OSRAM) 2015-05-14
JP5767733B2 JP5767733B2 (ja) 2015-08-19

Family

ID=39650527

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009551830A Active JP5596980B2 (ja) 2007-02-28 2008-02-27 ブラキュリポリペプチドおよび使用方法
JP2014083444A Active JP5767733B2 (ja) 2007-02-28 2014-04-15 ブラキュリポリペプチドおよび使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009551830A Active JP5596980B2 (ja) 2007-02-28 2008-02-27 ブラキュリポリペプチドおよび使用方法

Country Status (7)

Country Link
US (3) US8188214B2 (OSRAM)
EP (3) EP2444410A3 (OSRAM)
JP (2) JP5596980B2 (OSRAM)
AU (1) AU2008221383B2 (OSRAM)
CA (1) CA2678404C (OSRAM)
DK (1) DK2918598T3 (OSRAM)
WO (1) WO2008106551A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476928B (zh) 2010-12-09 2017-03-29 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
PL2685995T3 (pl) 2011-03-17 2017-10-31 Globeimmune Inc Kompozycje immunoterapeutyczne drożdże-Brachyury
WO2014043535A1 (en) * 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
EP2895191B1 (en) * 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
EP2976100B1 (en) 2013-03-19 2020-07-01 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
WO2017021776A1 (en) * 2015-07-31 2017-02-09 Bavarian Nordic A/S Promoters for enhancing expression in poxviruses
TWI748957B (zh) 2015-08-03 2021-12-11 美商環球免疫公司 經修飾之酵母-短尾畸型(Brachyury)免疫治療組合物
AU2016302237B2 (en) 2015-08-03 2022-08-04 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
EP3400009A2 (en) 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
JP6983819B2 (ja) * 2016-06-03 2021-12-17 エトゥビクス コーポレーション 前立腺がん関連抗原を使用する腫瘍ワクチン接種用の組成物及び方法
EP3464560A4 (en) * 2016-06-03 2020-01-15 Etubics Corporation TUMOR IMMUNOTHERAPY COMPOSITIONS AND METHODS INVOLVING HER2 / NEU
AU2018266103B2 (en) 2017-05-09 2024-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
US11170872B2 (en) 2019-11-05 2021-11-09 Apeel Technology, Inc. Prediction of latent infection in plant products
WO2022187963A1 (en) * 2021-03-10 2022-09-15 Provincial Health Services Authority Immunotherapy agents targeting brachyury and methods of using same

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
DE3751908T2 (de) 1986-07-07 1997-02-06 Centocor Inc Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
ES2056799T3 (es) 1987-07-17 1994-10-16 Rhein Biotech Ges Fur Biotechn Moleculas de adn codante para las regiones de control fmdh y gen estructural para una proteina que tiene una actividad de fmdh y su uso.
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
CA1340203C (en) 1987-09-16 1998-12-15 Noboru Yanagida Recombinant apivoxvirus
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
US5543508A (en) 1987-12-15 1996-08-06 Gene Shears Pty. Limited Ribozymes
DE68926504T2 (de) 1988-07-20 1996-09-12 David Segev Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
WO1991019803A1 (en) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
BR9206310A (pt) 1991-07-25 1995-04-25 Idec Pharma Corp Indução de respostas citotóxicas de linfócitos T.
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
CA2140343A1 (en) 1992-07-17 1994-02-03 Sean M. Sullivan Method and reagent for treatment of animal diseases
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
DE69332485T2 (de) 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5902880A (en) 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE209258T1 (de) 1994-07-15 2001-12-15 Akzo Nobel Nv Verwendung von rna-polymerase zur verbesserung von nukeinsaeure-amplifikationsverfahren
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
DK0784483T3 (da) 1994-10-03 2001-03-26 Us Gov Health & Human Serv Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6045908A (en) 1995-02-14 2000-04-04 Chisso Corporation Biodegradable fiber and non-woven fabric
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
WO1998037095A2 (en) 1997-02-24 1998-08-27 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
GB0023203D0 (en) * 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
JP2001510808A (ja) 1997-07-24 2001-08-07 イネックス ファーマシューティカルズ コーポレイション 核酸触媒の供給のためのリポソーム組成物
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
WO1999029864A1 (en) * 1997-12-09 1999-06-17 Virogenetics Corporation Recombinant vaccinia constructs expressing feline il-2, compositions and methods of use thereof
WO1999031262A2 (en) 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6849255B2 (en) * 1998-08-18 2005-02-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for enhancing cartilage repair
ATE370234T1 (de) 1998-09-01 2007-09-15 Us Gov Health & Human Serv Page-4, ein gage-ähnliches gen auf dem x- chromosom das von neoplastischer prostata, testis und uterus exprimiert wird, und dessen anwendungen
IL142216A0 (en) * 1998-09-30 2002-03-10 Corixa Corp A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
ATE408699T1 (de) 1999-03-10 2008-10-15 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
CN1378594A (zh) 1999-07-13 2002-11-06 美国政府健康及人类服务部 T-细胞受体r可变阅读框架蛋白(TARP)及其应用
CA2383213A1 (en) 1999-09-10 2001-03-15 Fordham University Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
AU2001259291B2 (en) * 2000-04-28 2006-11-23 Aventis Pasteur Limited Improved immunogenicity using a combination of DNA and vaccinia virus vector vaccines
AU2002303219A1 (en) * 2001-03-30 2002-10-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
US20030108890A1 (en) * 2001-05-30 2003-06-12 Baranova Anna Vjacheslavovna In silico screening for phenotype-associated expressed sequences
JP4594085B2 (ja) * 2002-06-06 2010-12-08 オンコセラピー・サイエンス株式会社 ヒト結腸癌に関連する遺伝子およびポリペプチド
JP2006516089A (ja) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
JPWO2006004182A1 (ja) * 2004-07-07 2008-04-24 日本電気株式会社 配列予測システム
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes

Similar Documents

Publication Publication Date Title
JP2014207903A5 (OSRAM)
JP2018148890A5 (OSRAM)
JP6794442B2 (ja) 新規な遺伝子組換えワクシニアウイルス
KR102684237B1 (ko) 개인 맞춤형 백신
JP7050044B2 (ja) ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター
FI3352776T3 (fi) Htt-repressoreita ja niiden käyttötapoja
JP2020530303A (ja) Car t細胞標的を発現する腫瘍溶解性ウイルス、及びその使用
CN109844104B (zh) 重组疫苗病毒及其用途
SG10201809075XA (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
FI3872085T3 (fi) Esimuotoiset virussekvenssit ja niiden käytöt
JP2016510989A5 (OSRAM)
JP2010519904A5 (OSRAM)
JP2019535311A5 (OSRAM)
JP2018521651A5 (OSRAM)
JP2019500907A5 (OSRAM)
RU2019112725A (ru) Композиции и способы для повышения стабильности трансгенов в поксвирусах
CA2909225C (en) Mutant vaccinia virus strains, uses thereof and method of producing the same
Sun et al. Genetically engineered recombinant adenovirus expressing interleukin‑2 for hepatocellular carcinoma therapy
CN103484462B (zh) Survivin启动子调控CD基因的重组腺病毒载体构建及其应用
Lousberg et al. Innate immune recognition of poxviral vaccine vectors
JP2025500867A (ja) 前立腺癌ワクチン及びその使用
HK1211622B (zh) 突变型痘苗病毒株、其用途及其制造方法
WO2025157196A1 (zh) 经修饰的痘苗病毒及其用途
RU2678056C1 (ru) Рекомбинантный онколитический штамм вируса осповакцины Л-ИВП_oncoB, содержащий гены, кодирующие гранулоцитарно-макрофагальный колониестимулирующий фактор и полиэпитопный иммуноген, состоящий из эпитопов антигенов, гиперэкспрессирующихся опухолевыми клетками при раке молочной железы
Selmi Precision Neurology in Multiple Sclerosis: Contemporary Advances and Future Perspectives